It’s been a while since I posted on the specialty insurance sector and I hope to post some more detailed thoughts and analysis when I get the time in the coming months. M&A activity has picked up recently with the XL/AXA and AIG/Validus deals being the latest examples of big insurers bulking up through M&A. Deloitte has an interesting report out on some of the factors behind the increased activity. The graph below shows the trend of the average price to book M&A multiples for P&C insurers.
click to enlarge
As regular readers will know, my preferred metric is price to tangible book value and the exhibit below shows that the multiples on recent deals are increasing and well above the standard multiple around 1.5X. That said, the prices are not as high as the silly prices of above 2X paid by Japanese insurers in 2015. Not yet anyway!
click to enlarge
Unless there are major synergies, either on the operating side or on the capital side (which seems to be AXA’s justification for the near 2X multiple on the XL deal), I just can’t see how a 2X multiple is justified in a mature sector. Assuming these firms can earn a 10% return on tangible assets over multiple cycles, a 2X multiple equates to 20X earnings!
Time will tell who the next M&A target will be….
Posted in Insurance Market
Tagged AIG, AXA, bermudian insurers, European reinsurers, insurance M&A action, insurance valuation, London based specialty insurers, london insurance market, M&A premium, price tangible book values, price to book value, price to tangible book value, reinsurance price to tangible book value, reinsurance pricing, reinsurance rates, risk based capital, specialty insurance sector, specialty insurer valuation, tangible book value, total return, Validus, XL Group
In a previous post, I compared the M&A action in the reinsurance and specialty insurance space to a rush for the bowl of keys in a swingers party. Well, the ACE/Chubb deal has brought the party to a new level where anything seems possible. The only rule now seems to be a size restriction to avoid a G-SIFI label (although MetLife and certain US stakeholders are fighting to water down those proposals for insurers).
I expanded the number of insurers in my pool for an update of the tangible book multiples (see previous post from December) as per the graphic below. As always, these figures come with a health warning in that care needs to be taken when comparing US, European and UK firms due to the differing accounting treatment (for example I have kept the present value of future profits as a tangible item). I estimated the 2015 ROE based upon Q1 results and my view of the current market for the 2011 to 2015 average.
click to enlarge
I am not knowledgeable enough to speculate on who may be the most likely next couplings (for what its worth, regular readers will know I think Lancashire will be a target at some stage). This article outlines who Eamonn Flanagan at Shore Capital thinks is next, with Amlin being his top pick. What is clear is that the valuation of many players is primarily based upon their M&A potential rather than the underlying operating results given pricing in the market. Reinsurance pricing seems to have stabilised although I suspect policy terms & conditions remains an area of concern. On the commercial insurance side, reports from market participants like Lockton (see here) and Towers Watson (see graph below) show an ever competitive market.
click to enlarge
Experience has thought me that pricing is the key to future results for insurers and, although the market is much more disciplined than the late 1990s, I think many will be lucky to produce double-digit ROEs in the near term on an accident year basis (beware those dipping too much into the reserve pot!).
I am also nervous about the amount of unrealised gains which are inflating book values that may reverse when interest rates rise. For example, unrealised gains make up 8%, 13% and 18% of the Hartford, Zurich, and Swiss Re’s book value respectively as at Q1. So investing primarily to pick up an M&A premium seems like a mugs game to me in the current market.
M&A obviously brings considerable execution risk which may result in one plus one not equalling two. Accepting that the financial crisis hit the big guys like AIG and Hartford pretty hard, the graph below suggests that being too big may not be beautiful where average ROE (and by extension, market valuation) is the metric for beauty.
click to enlarge
In fact, the graph above suggests that the $15-$25 billion range in terms of premiums may be the sweet spot for ROE. Staying as a specialist in the $2-7 billion premium range may have worked in the past but, I suspect, will be harder to replicate in the future.
Posted in Insurance Market
Tagged 99% T-VaR, 99.5% VaR, ACE Chubb merger, Amlin, bermudian insurers, commercial insurance pricing, dilution of terms and conditions, European reinsurers, G-SIFI, Hartford, insurance M&A action, insurance pricing pressure, insurance valuation, Lancashire valuation, London based specialty insurers, london insurance market, M&A premium, MetLife, policy terms & conditions, price tangible book values, price to tangible book value, reinsurance price to tangible book value, reinsurance pricing, reinsurance rates, risk adjusted premiums, risk based capital, Shore Capital, specialty insurance sector, specialty insurer valuation, swingers party, Swiss Re, tangible book multiples, total return, unrealised book value, unrealised capital gains, VaR shock insurance, Zurich
In an opinion piece in the FT in 2008, Alan Greenspan stated that any risk model is “an abstraction from the full detail of the real world”. He talked about never being able to anticipate discontinuities in financial markets, unknown unknowns if you like. It is therefore depressing to see articles talk about the “VaR shock” that resulted in the Swissie from the decision of the Swiss National Bank (SNB) to lift the cap on its FX rate on the 15th of January (examples here from the Economist and here in the FTAlphaVille). If traders and banks are parameterising their models from periods of unrepresentative low volatility or from periods when artificial central bank caps are in place, then I worry that they are not even adequately considering known unknowns, let alone unknown unknowns. Have we learned nothing?
Of course, anybody with a brain knows (that excludes traders and bankers then!) of the weaknesses in the value-at-risk measure so beloved in modern risk management (see Nassim Taleb and Barry Schachter quotes from the mid 1990s on Quotes page). I tend to agree with David Einhorn when, in 2008, he compared the metric as being like “an airbag that works all the time, except when you have a car accident“. A piece in the New York Times by Joe Nocera from 2009 is worth a read to remind oneself of the sad topic.
This brings me to the insurance sector. European insurance regulation is moving rapidly towards risk based capital with VaR and T-VaR at its heart. Solvency II calibrates capital at 99.5% VaR whilst the Swiss Solvency Test is at 99% T-VaR (which is approximately equal to 99.5%VaR). The specialty insurance and reinsurance sector is currently going through a frenzy of deals due to pricing and over-capitalisation pressures. The recently announced Partner/AXIS deal follows hot on the heels of XL/Catlin and RenRe/Platinum merger announcements. Indeed, it’s beginning to look like the closing hours of a swinger’s party with a grab for the bowl of keys! Despite the trend being unattractive to investors, it highlights the need to take out capacity and overhead expenses for the sector.
I have posted previously on the impact of reduced pricing on risk profiles, shifting and fattening distributions. The graphic below is the result of an exercise in trying to reflect where I think the market is going for some businesses in the market today. Taking previously published distributions (as per this post), I estimated a “base” profile (I prefer them with profits and losses left to right) of a phantom specialty re/insurer. To illustrate the impact of the current market conditions, I then fattened the tail to account for the dilution of terms and conditions (effectively reducing risk adjusted premia further without having a visible impact on profits in a low loss environment). I also added risks outside of the 99.5%VaR/99%T-VaR regulatory levels whilst increasing the profit profile to reflect an increase in risk appetite to reflect pressures to maintain target profits. This resulted in a decrease in expected profit of approx. 20% and an increase in the 99.5%VaR and 99.5%T-VaR of 45% and 50% respectively. The impact on ROEs (being expected profit divided by capital at 99.5%VaR or T-VaR) shows that a headline 15% can quickly deteriorate to a 7-8% due to loosening of T&Cs and the addition of some tail risk.
click to enlarge
For what it is worth, T-VaR (despite its shortfalls) is my preferred metric over VaR given its relative superior measurement of tail risk and the 99.5%T-VaR is where I would prefer to analyse firms to take account of accumulating downside risks.
The above exercise reflects where I suspect the market is headed through 2015 and into 2016 (more risky profiles, lower operating ROEs). As Solvency II will come in from 2016, introducing the deeply flawed VaR metric at this stage in the market may prove to be inappropriate timing, especially if too much reliance is placed upon VaR models by investors and regulators. The “full detail of the real world” today and in the future is where the focus of such stakeholders should be, with much less emphasis on what the models, calibrated on what came before, say.
Posted in Insurance Market, Insurance Models
Tagged 1 in 10000 return period, 99% T-VaR, 99.5% VaR, adverse selection, Alan Greenspan, Barry Schachter, climate models, David Einhorn, deeply flawed VaR metric, dilution of terms and conditions, discontinuities in financial markets, economic capital models, economic modelling, European insurance regulation, exchange rates, fat tails, financial engineering, financial innovation, financial models, FTAlphaVille, game theory, imperfect art of modelling, insurance capital models, insurance pricing pressure, internal capital models, internal models, Joe Nocera, loss exceedance probability distribution, modern risk management, Nassim Taleb, New York Times, probability models, probability of default, probability of occurrence, reducing risk adjusted premiums, Return on equity, return period, risk based capital, risk model, solvency ii, Solvency II calibration, Solvency II standard formula, specialty insurance sector, Swiss National Bank, Swiss Solvency Test, Swissie, tail value at risk, Tails of VaR, the Economist, unknown unknowns, unrepresentative low volatility, value at risk, VaR and T-VaR, VaR shock